Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Radiotherapy remains a fundamental treatment for prostate cancer, and recent developments in precision medicine and ...

Insights from AUA 2025, including anticipated presentations, key takeaways, and how new research in metastatic prostate ...

Dr Mohammad Mahmoud shares anticipated updates on evolving local treatments, PSMA-based therapies, and impactful genetic studies.

Cleveland Clinic Abu Dhabi, part of the M42 group, has achieved a historic milestone in global healthcare. In collaboration ...